Avzivi® (BAT1706) is Bio-Thera Solution’second FDA approved product in the United States Avzivi® is the second biosesimilar researched,developed, and manufactured by a Chinese pharmaceutical company to receive FDAapproval in the United States Guangzhou, China – December 7, 2023 – Bio-TheraSolu...
DetailsGUANGZHOU,China, October 24, 2023 -- Bio-Thera Solutions, Ltd (688177:SH), acommercial-stage biopharmaceutical company developing a pipeline of biosesimilarsand innovative assets, announced that the National Health Surveillance Agency(“ANVISA”) published the approval of the certification of good m...
TOFIDENCE is Bio-Thera’s first productapproved by USFDA. TOFIDENCE is the first monoclonal antibodydrug researched, developed, and manufactured by a Chinese pharmaceuticalcompany to receive FDA approval in the United States TOFIDENCE is the first biosesimilar toActemra approved by USFDA GUANGZHOU, C...
GUANGZHOU,China --(PR Newswire) -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceuticalcompany developing a pipeline of innovative and biosesimilars, today announcedpositive Phase 1 clinical data for BAT8006 (Folate-Receptor-α-ADC) as part of apresentation of the clinical result...
